GENMAB - Dusseldorf Stock Exchang (GE9 DU) stock market data APIs
€190.4894
-0.57(-0.3%)
as of July 18, 2025
Try our APIs with
free plan!
GENMAB - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GE9.DU.
Prev. Close
190.4894
Open
189.9211
High
189.6821
Low
189.9211
52 wk Range
157-263.3
Market Cap
22 148 M
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GENMAB - Dusseldorf Stock Exchang data using free add-ons & libraries
Get GENMAB - Dusseldorf Stock Exchang Fundamental Data
GENMAB - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GENMAB - Dusseldorf Stock Exchang News
New
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
Genmab A/S Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal en...
UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT
Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 25, UBS analyst Xian Deng maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) and set a price targ...
Genmab (GMAB) Announced Results From its EPCORE NHL-2 Trial
Genmab A/S (NASDAQ:GMAB) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 15, Genmab A/S (NASDAQ:GMAB) announced results from its EPCORE NHL-2 trial, Arm 10. The study te...
M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates
Investing.com -- Morgan Stanley has begun coverage of Genmab (CSE:GMAB) (NASDAQ:GMAB) with an Equal-Weight rating and a price objective of $24, reduced slightly from the previous $25 target. The Wa...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
